Literature DB >> 22277901

Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer.

Wen-Hong Kuo1, Po-Han Lin, Ai-Chu Huang, Yin-Hsiu Chien, Tsang-Pai Liu, Yen-Shen Lu, Li-Yuan Bai, Aaron M Sargeant, Ching-Hung Lin, Ann-Lii Cheng, Fon-Jou Hsieh, Wuh-Liang Hwu, King-Jen Chang.   

Abstract

Although evidence suggests an importance of genetic factors in the development of breast cancer in Taiwanese (ethnic Chinese) women, including a high incidence of early-onset and secondary contralateral breast cancer, a major breast cancer predisposition gene, BRCA1, has not been well studied in this population. In fact, the carcinogenic impacts of many genetic variants of BRCA1 are unknown and classified as variants of uncertain significance (VUS). It is therefore important to establish a method to characterize the BRCA1 VUSs and understand their role in Taiwanese breast cancer patients. Accordingly, we developed a multimodel assessment strategy consisting of a prescreening portion and a validated functional assay to study breast cancer patients with early-onset, bilateral or familial breast cancer. We found germ-line BRCA1 mutations in 11.1% of our cohort and identified one novel missense mutation, c.5191C>A. Two genetic variants were initially classified as VUSs (c.1155C>T and c.5191C>A). c.1155C>T is not predicted to be deleterious in the prescreening portion of our assessment strategy. c.5191C>A, on the other hand, causes p.T1691K, which is predicted to have high deleterious probability because of significant structural alteration, a high deleterious score in the predictive programs and, clinically, triple negative characteristics in breast tumors. This mutant is confirmed by transcription activation and yeast growth-inhibition assays. In conclusion, we show as high a prevalence of germ-line BRCA1 mutation in high-risk Taiwanese patients as in Caucasians and demonstrate a useful strategy for studying BRCA1 VUSs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22277901     DOI: 10.1038/jhg.2011.142

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  12 in total

Review 1.  Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.

Authors:  Ava Kwong; Vivian Y Shin; John C W Ho; Eunyoung Kang; Seigo Nakamura; Soo-Hwang Teo; Ann S G Lee; Jen-Hwei Sng; Ophira M Ginsburg; Allison W Kurian; Jeffrey N Weitzel; Man-Ting Siu; Fian B F Law; Tsun-Leung Chan; Steven A Narod; James M Ford; Edmond S K Ma; Sung-Won Kim
Journal:  J Med Genet       Date:  2015-07-17       Impact factor: 6.318

2.  Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.

Authors:  Rumyana Ivanova Dodova; Atanaska Velichkova Mitkova; Daniela Rosenova Dacheva; Lina Basam Hadjo; Alexandrina Ivanova Vlahova; Margarita Stoyanova Taushanova -Hadjieva; Spartak Stoyanov Valev; Marija Mitko Caulevska; Stanislava Dimitrova Popova; Ivan Emilov Popov; Tihomir Iliichev Dikov; Theophil Angelov Sedloev; Atanas Stefanov Ionkov; Konstanta Velinova Timcheva; Svetlana Liubomirova Christova; Ivo Marinov Kremensky; Vanio Ivanov Mitev; Radka Petrova Kaneva
Journal:  BMC Cancer       Date:  2015-07-17       Impact factor: 4.430

Review 3.  A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Authors:  Fatemeh Karami; Parvin Mehdipour
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

4.  Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic.

Authors:  Lise B Ahlborn; Mette Dandanell; Ane Y Steffensen; Lars Jønson; Finn C Nielsen; Thomas V O Hansen
Journal:  Breast Cancer Res Treat       Date:  2015-02-28       Impact factor: 4.872

5.  High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.

Authors:  Muhammad Usman Rashid; Noor Muhammad; Seerat Bajwa; Saima Faisal; Muhammad Tahseen; Justo Lorenzo Bermejo; Asim Amin; Asif Loya; Ute Hamann
Journal:  BMC Cancer       Date:  2016-08-23       Impact factor: 4.430

6.  iRegNet3D: three-dimensional integrated regulatory network for the genomic analysis of coding and non-coding disease mutations.

Authors:  Siqi Liang; Nathaniel D Tippens; Yaoda Zhou; Matthew Mort; Peter D Stenson; David N Cooper; Haiyuan Yu
Journal:  Genome Biol       Date:  2017-01-18       Impact factor: 13.583

7.  Germline breast cancer susceptibility gene mutations and breast cancer outcomes.

Authors:  Yong Alison Wang; Jhih-Wei Jian; Chen-Fang Hung; Hung-Pin Peng; Chi-Fan Yang; Hung-Chun Skye Cheng; An-Suei Yang
Journal:  BMC Cancer       Date:  2018-03-22       Impact factor: 4.430

8.  The bidirectional association among female hormone-related cancers: breast, ovary, and uterine corpus.

Authors:  Min-Chi Chen; Kuan-Der Lee; Chang-Hsien Lu; Ting-Yao Wang; Shih-Hao Huang; Chao-Yu Chen
Journal:  Cancer Med       Date:  2018-04-16       Impact factor: 4.452

9.  Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.

Authors:  Po-Han Lin; Wen-Hung Kuo; Ai-Chu Huang; Yen-Shen Lu; Ching-Hung Lin; Sung-Hsin Kuo; Ming-Yang Wang; Chun-Yu Liu; Fiona Tsui-Fen Cheng; Ming-Hsin Yeh; Huei-Ying Li; Yu-Hsuan Yang; Yu-Hua Hsu; Sheng-Chih Fan; Long-Yuan Li; Sung-Liang Yu; King-Jen Chang; Pei-Lung Chen; Yen-Hsuan Ni; Chiun-Sheng Huang
Journal:  Oncotarget       Date:  2016-02-16

10.  The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.

Authors:  Pi-Lin Sung; Kuo-Chang Wen; Yi-Jen Chen; Ta-Chung Chao; Yi-Fang Tsai; Ling-Ming Tseng; Jian-Tai Timothy Qiu; Kuan-Chong Chao; Hua-Hsi Wu; Chi-Mu Chuang; Peng-Hui Wang; Chi-Ying F Huang
Journal:  PLoS One       Date:  2017-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.